Companies / Financials
CME
CME Group
Financial Exchanges & Data
Financial Exchanges & DataAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health75
Growth51
Profitability100
Cash generationn/a
Balance sheetn/a
Dilution control75
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)13.0%Revenue growth (FY)6.4%Revenue CAGR (3y)9.1%Gross margin—Operating margin64.9%Net margin62.5%Free cash flow margin64.3%R&D / revenue—Stock comp / revenue1.5%Net debt / operating cash flow-1.03xCurrent ratio1.03Diluted share count change0.1%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $4.7B | $5.0B | $5.6B | $6.1B | $6.5B |
| Operating income | $2.6B | $3.0B | $3.4B | $3.9B | $4.2B |
| Net income | $2.6B | $2.7B | $3.2B | $3.5B | $4.1B |
| Operating cash flow | $2.4B | $3.1B | $3.5B | $3.7B | $4.3B |
| Capital expenditure | $127M | $90M | $76M | $94M | $84M |
| Free cash flow | $2.3B | $3.0B | $3.4B | $3.6B | $4.2B |
| Stock-based comp | $75M | $84M | $83M | $90M | $95M |
| Dividends | $2.2B | $2.6B | $3.2B | $3.6B | $3.9B |
| Cash | $2.8B | $2.7B | $2.9B | $2.9B | $4.4B |
| Total debt | $749M | $16M | $0 | $750M | $0 |
| Equity | $27.4B | $26.9B | $26.7B | $26.5B | $28.7B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.